Сartalaх
Distribution of patients by diagnosis, sex and age Table 1
Diagnosis Age Men Women Total
(years)
Control group Primary Control Primary Control group Primary
group group group group
Osteoarthritis of the 59-78 6 7 3 3 9 10
knee joints
Osteochondrosis of 45-69 7 6 8 9 15 15
the spine
Osteoporosis 45-65 - - 7 8 7 8
Total: 13 13 11 12 31 33
RESEARCH METHODS
СARTALAХ® efficiency assessment was carried out by analyzing the patient complaints progression and
the objective parameters: general clinical analysis of blood and urine, biochemical blood analysis, X-ray
examination.
RESEARCH RESULTS
It is important to note that radiology symptoms of degenerate and dystrophic diseases of joints and spine
are objective diagnostic criteria of pathological process development stage and are of high prognostic
importance for the drug therapy carried out.
The use of СARTALAХ® in patients with knee joint osteoarthritis contributed to decreased pain
syndrome and increased joint mobility in 68.5% of cases. At the same time, pain symptoms stopped
mostly in radiologically identifiable initial stages of the disease: joint space narrowing between patella
and femur, lateral osteophytes of the patella and femoral condyle. There were no considerable dynamics
of roentgenological symptoms during this period.
In patients in the advanced stage of arthrosis, a similar but less pronounced dynamic of subjective
indicators was observed. Such subjective sensations were very favorable since this stage of the disease
was diagnosed in patients of the senior age group.
In patients with osteochondrosis of the lumbar spine, using СARTALAХ® against the background of
complex therapy helped reduce pain in 53.7% of cases. In these cases, long-term (at least 45-60 days) use
of СARTALAХ® smoothed the pain symptoms arising from pressure on the spine and lower extremities
and increased the spine’s mobility. Such changes were most typical for middle-aged people. Age-related
disease progression, accompanied by typical radiological symptoms (narrowing of the space between
adjacent vertebral bodies due to flattening degenerate intervertebral disks; anterior and posterior
osteophytes of the vertebral bodies, arthritic changes of posterior and lateral intervertebral joints in the
form of narrowing of the spaces, irregularity of the contours, osteophytes at the margins of the joint ends,
and changes of the configuration of intervertebral foramens), resulted in the development of spondylosis
and spondyloarthrosis, and the formation of neurodystrophic and neurovascular syndromes.
After long-term administration of the drug, the patients with osteoporosis have shown stabilization
of metabolic processes in the bone tissue: reduction in the number of typical fractures, considerable
acceleration of restoration of the function of the musculoskeletal system, and decrease in the time of
stay in the hospital.
All patients showed a significant improvement in the main symptoms of their diseases.
СARTALAХ® does not cause side effects, complications, or drug dependence.
Thus the results of the study carried out prove the efficiency of СARTALAХ® and practicality of its use
for complex treatment and prevention of degenerate and dystrophic diseases of the joints and vertebral
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.